Artiva Biotherapeutics, Inc. (ARTV) has a negative trailing P/E of -2.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -51.21%.
Criteria proven by this page:
Overall SharesGrow Score: 63/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2020 | -11.7 | 0.00 | -9.78 | 0.00 | - |
| 2021 | -2.9 | -0.01 | -2.37 | 105.39 | - |
| 2022 | -3.6 | 0.19 | -1.50 | 42.79 | - |
| 2023 | -10.1 | 0.16 | -1.72 | 8.34 | - |
| 2024 | -4.2 | -0.01 | 1.32 | 978.41 | - |
| 2025 | -1.3 | 0.04 | 0.95 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2020 | $-1.02 | $0.00 | $-17.99M | - |
| 2021 | $-4.08 | $2M | $-71.83M | -3587.7% |
| 2022 | $-3.32 | $4.93M | $-58.39M | -1184.1% |
| 2023 | $-1.19 | $33.49M | $-27.7M | -82.7% |
| 2024 | $-5.20 | $251K | $-58.49M | -23304% |
| 2025 | $-3.43 | $0.00 | $-83.87M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.38 | $-4.24 – $-2.54 | $0.00 | $0.00 – $0.00 | 4 |
| 2027 | $-2.80 | $-4.30 – $-1.61 | $0.00 | $0.00 – $0.00 | 4 |
| 2028 | $-2.41 | $-3.96 – $-1.09 | $1.68M | $1.68M – $1.68M | 5 |
| 2029 | $-2.17 | $-2.17 – $-2.17 | $60.04M | $60.04M – $60.04M | 1 |
| 2030 | $-1.16 | $-1.16 – $-1.16 | $164.82M | $164.82M – $164.82M | 1 |
